AGR2 and breast neoplasm: Indeed, the downregulation of the “Estrogen-mediated S phase entry” pathway in breast tumors with high AGR2 mRNA expression—suggested by IPA analyses in both the METABRIC and TCGA datasets—may represent breast tumors that overexpress AGR2 to become resistant to estrogen therapy (Table 5).